Phase i study of terameprocol in patients with recurrent high-grade glioma

Neuro-Oncology

Volumn 14, Issue 4, 2012, Pages 511-517

  Grossman, Stuart A ^a   Ye, Xiaobu ^a   Peereboom, David ^b   Rosenfeld, Myrna R ^c   Mikkelsen, Tom ^e   Supko, Jeffrey G ^d   Desideri, Serena ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d HENRY FORD HOSPITAL   (United States)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

glioblastoma; high grade glioma; phase I trial; terameprocol; transcription inhibitor

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; ENZYME INDUCING ANTISEIZURE DRUG; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PRIMIDONE; TERAMEPROCOL; UNCLASSIFIED DRUG;

ADULT; AGED; ANTICONVULSANT THERAPY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW DISEASE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; DRUG DOSE ESCALATION; DRUG TOLERABILITY; FEMALE; GLIOMA; HEART DISEASE; HUMAN; HYPOXIA; ILEUS; INTERSTITIAL NEPHRITIS; KARNOFSKY PERFORMANCE STATUS; LUNG DISEASE; MALE; MAXIMUM TOLERATED DOSE; METABOLIC DISORDER; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; NEUROLOGIC DISEASE; OVERALL SURVIVAL; PAIN; PHASE 1 CLINICAL TRIAL; RECURRENT HIGH GRADE GLIOMA; SEIZURE; SKIN DISEASE; SOFT TISSUE DISEASE; TUMOR RECURRENCE;

ADULT; AGED; ANTICONVULSANTS; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GLIOMA; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NORDIHYDROGUAIARETIC ACID; TREATMENT OUTCOME;

EID: 84859519936     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nor230     Document Type: Article

References (42)

1. Grossman SA, Ye X, Piantadosi S, et al. Survival of patients with newly diagnosed glioblastoma treated with radiation and temozolomide in research studies in the United States. Clin Cancer Res. 2010;16:2443-2449.
2. Arteaga S, Andrade-Cetto A, Cardenas R. Larrea tridentata (creosote bush), an abundant plant of Mexican and US-American deserts and its metabolite nordihydroguaiaretic acid. J Ethnopharmacol. 2005;98:231-239. (Pubitemid 40461975)
3. Lu JM, Nurko J, Weakley SM, et al. Molecular mechanisms and clinical applications of nordihydroguaiaretic acid (NDGA) and its derivatives: An update. Med Sci Monit. 2010;16:RA93-100.
4. Floriano-Sanchez E, Villanueva C, Medina-Campos ON, et al. Nordihydroguaiaretic acid is a potent in vitro scavenger of peroxynitrite, singlet oxygen, hydroxyl radical, superoxide anion and hypochlorous acid and prevents in vivo ozone-induced tyrosine nitration in lungs. Free Radic Res. 2006;40:523-533.
5. Sheikh NM, Philen RM, Love LA. Chaparral-associated hepatotoxicity. Arch Intern Med. 1997;157:913-919. (Pubitemid 28337043)
6. Craigo J, Callahan M, Huang RC, DeLucia AL. Inhibition of human papillomavirus type 16 gene expression by nordihydroguaiaretic acid plant lignan derivatives. Antiviral Res. 2000;47:19-28. (Pubitemid 30621393)
7. Huang RC, Li Y, Giza PE, et al. Novel antiviral agent tetraglycylated nordihydroguaiaretic acid hydrochloride as a host-dependent viral inhibitor. Antiviral Res. 2003;58:57-64. (Pubitemid 36507222)
8. Chen H, Teng L, Li JN, et al. Antiviral activities of methylated nordihydroguaiaretic acids. 2. targeting herpes simplex virus replication by the mutation insensitive transcription inhibitor tetra-O-methyl-NDGA. J Med Chem. 1998;41:3001-3007. (Pubitemid 28359935)
9. Hwu JR, Tseng WN, Gnabre J, Giza P, Huang RC. Antiviral activities of methylated nordihydroguaiaretic acids. 1. synthesis, structure identification, and inhibition of tat-regulated HIV transactivation. J Med Chem. 1998;41:2994-3000. (Pubitemid 28359934)
10. Park R, Giza PE, Mold DE, Huang RC. Inhibition of HSV-1 replication and reactivation by the mutation-insensitive transcription inhibitor tetra-O-glycyl-nordihydroguaiaretic acid. Antiviral Res. 2003;58:35-45. (Pubitemid 36507220)
11. Heller JD, Kuo J, Wu TC, Kast WM, Huang RC. Tetra-O-methyl nordihydroguaiaretic acid induces G2 arrest in mammalian cells and exhibits tumoricidal activity in vivo. Cancer Res. 2001;61:5499-5504. (Pubitemid 32694933)
12. Park R, Chang CC, Liang YC, et al. Systemic treatment with tetra-O-methyl nordihydroguaiaretic acid suppresses the growth of human xenograft tumors. Clin Cancer Res. 2005;11:4601-4609. (Pubitemid 40825651)
13. Smolewski P. Terameprocol, a novel site-specific transcription inhibitor with anticancer activity. IDrugs. 2008;11:204-214. (Pubitemid 351323375)
14. Chang CC, Heller JD, Kuo J, Huang RC. Tetra-O-methyl nordihydroguaiaretic acid induces growth arrest and cellular apoptosis by inhibiting Cdc2 and survivin expression. Proc Natl Acad Sci USA. 2004;101:13239-13244. (Pubitemid 39209649)
15. Cheung CH, Cheng L, Chang KY, Chen HH, Chang JY. Investigations of survivin: The past, present and future. Front Biosci. 2011; 16:952-961.
16. Ryan BM, O'Donovan N, Duffy MJ. Survivin: A new target for anti-cancer therapy. Cancer Treat Rev. 2009;35:553-562.
17. Altieri DC. Survivin and IAP proteins in cell-death mechanisms. Biochem J. 2010;430:199-205.
18. Dunphy FR, Dukelow KK. Provenzal JandCrawford J, Phase I clinical results of intralesional injection of tetro-O-methyl nordihydrogualaretic acid (M4N) in refractory head and neck cancer. Proc Am Soc Clin Oncol. 2004;23:#5614.
19. Lopez RA, Goodman AB, Rhodes M, Blomberg JA, Heller J. The anticancer activity of the transcription inhibitor terameprocol (meso-tetra-O-methyl nordihydroguaiaretic acid) formulated for systemic administration. Anticancer Drugs. 2007;18:933-939. (Pubitemid 47220712)
20. Infante JR. Terameprocol infusion for solid tumors. Chemotherapy Foundation Symposium XXVI. 2008. Available at http://www. chemotherapyfoundationsymposium.org/meetingarchives-tcf2008-main.html. Accessed January 5, 2012.
21. Tibes R, McDonagh KT, Lekakis L, Frazer N, Mohrland S, Dawn B. Phase I study of the novel survivin and cdc2/CDK1 inhibitor terameprocol in patients with advanced leukemias. Blood. 2009;114:#1039.
22. Eder JP, Jr, Supko JG, Lynch T, et al. Phase I trial of the colloidal dispersion formulation of 9-amino-20(S)-camptothecin administered as a 72-hour continuous intravenous infusion. Clin Cancer Res. 1998;4:317-324. (Pubitemid 28122744)
23. Gibaldi M, Perrier D. Pharmacokinetics. New York, Decker, 1982.
24. Macdonald DR, Cascino TL, Schold SC, Jr, Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol. 1990;8:1277-1280. (Pubitemid 20195640)
25. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
26. Hwu JR, Hsu CI, Hsu MH, Liang YC, Huang RC, Lee YC. Glycosylated nordihydroguaiaretic acids as anti-cancer agents. Bioorg Med Chem Lett. 2011;21:380-382.
27. Abd-Elazem IS, Chen HS, Bates RB, Huang RC. Isolation of two highly potent and non-toxic inhibitors of human immunodeficiency virus type 1 (HIV-1) integrase from salvia miltiorrhiza. Antiviral Res. 2002;55:91-106. (Pubitemid 34655645)
28. Gnabre JN, Brady JN, Clanton DJ, et al. Inhibition of human immunodeficiency virus type 1 transcription and replication by DNA sequence-selective plant lignans. Proc Natl Acad Sci USA. 1995;92:11239-11243.
29. Pollara JJ, Laster SM, Petty IT. Inhibition of poxvirus growth by terameprocol, a methylated derivative of nordihydroguaiaretic acid. Antiviral Res. 2010;88:287-295.
30. Guha M, Altieri DC. Survivin as a global target of intrinsic tumor suppression networks. Cell Cycle. 2009;8:2708-2710.
31. Huang RC, Chang CC, Mold D. Survivin-dependent and-independent pathways and the induction of cancer cell death by tetra-O-methyl nordihydroguaiaretic acid. Semin Oncol. 2006;33:479-485. (Pubitemid 44142741)
32. Sun Y, Giacalone NJ, Lu B. Terameprocol (tetra-O-methyl nordihydroguaiaretic acid), an inhibitor of Sp1-mediated survivin transcription, induces radiosensitization in non-small cell lung carcinoma. J Thorac Oncol. 2011;6:8-14.
33. Famulski JK, Vos LJ, Rattner JB, Chan GK. Dynein/Dynactin-mediated transport of kinetochore components off kinetochores and onto spindle poles induced by nordihydroguaiaretic acid. PLoS One. 2011;6:e16494.
34. Chang CC, Liang YC, Klutz A, et al. Reversal of multidrug resistance by two nordihydroguaiaretic acid derivatives, M4N and maltose-M3N, and their use in combination with doxorubicin or paclitaxel. Cancer Chemother Pharmacol. 2006;58:640-653. (Pubitemid 44167390)
35. Lambert JD, Meyers RO, Timmermann BN, Dorr RT. Tetra-O- methylnordihydroguaiaretic acid inhibits melanoma in vivo. Cancer Lett. 2001;171:47-56. (Pubitemid 32727355)
36. Mak DH, Schober WD, Chen W, Heller J, Andreeff M, Carter BZ. Tetra-O-methyl nordihydroguaiaretic acid inhibits growth and induces death of leukemia cells independent of Cdc2 and survivin. Leuk Lymphoma. 2007;48:774-785. (Pubitemid 46605551)
37. Meyers RO, Lambert JD, Hajicek N, Pourpak A, Kalaitzis JA, Dorr RT. Synthesis, characterization, and anti-melanoma activity of tetra-O-substituted analogs of nordihydroguaiaretic acid. Bioorg Med Chem Lett. 2009;19:4752-4755.
38. Zhu X, Ma Y, Liu D. Novel agents and regimens for acute myeloid leukemia: 2009 ASH annual meeting highlights. J Hematol Oncol. 2010;3:17.
39. Hansel DE, Dhara S, Huang RC, et al. CDC2/CDK1 expression in esophageal adenocarcinoma and precursor lesions serves as a diagnostic and cancer progression marker and potential novel drug target. Am J Surg Pathol. 2005;29:390-399. (Pubitemid 40321976)
40. Khanna N, Dalby R, Connor A, Church A, Stern J, Frazer N. Phase I clinical trial of repeat dose terameprocol vaginal ointment in healthy female volunteers. Sex Transm Dis. 2008;35:577-582.
41. Khanna N, Dalby R, Tan M, Arnold S, Stern J, Frazer N. Phase I/II clinical safety studies of terameprocol vaginal ointment. Gynecol Oncol. 2007;107:554-562. (Pubitemid 350160872)
42. Day T, Gillespie M, Ernster J. Open label phase I dose escalation study of intralesional injection of M4N in head and neck cancer. International Conference of Head and Neck Cancer. 2004;6s:197.